5 big analyst AI moves: Nvidia guidance warning; Snowflake, Palo Alto upgraded
MINNEAPOLIS - Donaldson Company, Inc. (NYSE:DCI), a global leader in filtration products and solutions, has declared an 11.1% increase in its regular cash dividend, raising it to 30.0 cents per share from the previous 27.0 cents. This dividend is due for payment on June 30, 2025, to shareholders of record as of June 16, 2025. The company, currently valued at $8.3 billion, offers a dividend yield of 1.55%, according to InvestingPro data.
The company’s consistent performance is highlighted by its inclusion in the S&P High-Yield Dividend Aristocrats Index. This increase marks Donaldson’s 29th consecutive year of annual dividend growth, showcasing its commitment to delivering shareholder value. Donaldson has a long-standing history of providing dividends, with an uninterrupted quarterly cash dividend distribution for 69 years.
Donaldson, established in 1915, operates over 140 locations across six continents. The company has a diverse workforce that collaborates with customers ranging from small business owners to major original equipment manufacturers (OEMs) and research and development organizations. Donaldson addresses complex filtration challenges across three primary segments: Mobile Solutions, Industrial Solutions, and Life Sciences.
The information reported is based on a press release statement from Donaldson Company, Inc.
In other recent news, Donaldson Company, Inc. has announced the upcoming retirement of Thomas R. Scalf, President of Enterprise Operations and Supply Chain, effective August 1, 2025. Mr. Scalf will continue to support the company through a consulting agreement until the end of 2025, receiving $40,000 monthly. The company has yet to name a successor. Meanwhile, Stifel analysts have adjusted their outlook on Donaldson, reducing the stock price target from $70 to $63 and maintaining a Hold rating. This revision reflects concerns about a potential industrial recession in the United States, which could negatively impact capital and operating expenditures. Supply chain disruptions are also anticipated to affect Donaldson’s production capabilities. In another development, Ginkgo Bioworks has secured a $29 million contract from ARPA-H to develop a new method for producing active pharmaceutical ingredients using wheat germ cell-free systems. This initiative aims to decentralize and stabilize the manufacturing of essential medicines in the United States. Ginkgo will collaborate with several partners, including Isolere Bio by Donaldson, to enhance domestic pharmaceutical manufacturing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.